Braveheart Bio

BRVE · NASDAQ · Healthcare

$21.42

▼ $21.42 (-0.09%)

1D 7D 1M 3M 1Y All

Day range

$20.77 – $21.98

Year range

$19.88 – $32.00

Open

$21.44

Previous close

—

Market cap

$1.51B

Volume (24h)

$165.0K

Volume (52w)

$3.53M

Performance

▲ 1.66%

▼ -20.52%

▼ -28.12%

YTD

▼ -28.12%

All-time

▼ -28.12%

Key statistics

P/E ratio

-8.53

EPS (TTM)

$-2.51

Dividend yield

—

Dividend (TTM)

—

Payout ratio

—

Shares outstanding

70.7M

About Braveheart Bio

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

Visit website

Country: United States of America

LLY Eli Lilly and Company	$1139.65	-1.23%
JNJ Johnson & Johnson	$256.11	-1.42%
ABBV AbbVie	$260.91	0.45%
MRK Merck & Co.	$143.38	-0.27%
UNH UnitedHealth Group Incorp…	$368.09	0.81%